Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EPS (Basic): 2009-2025

Historic EPS (Basic) for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $0.06.

  • Amicus Therapeutics' EPS (Basic) rose 400.00% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.04, marking a year-over-year increase of 88.24%. This contributed to the annual value of -$0.18 for FY2024, which is 64.71% up from last year.
  • Per Amicus Therapeutics' latest filing, its EPS (Basic) stood at $0.06 for Q3 2025, which was up 175.00% from -$0.08 recorded in Q2 2025.
  • Amicus Therapeutics' EPS (Basic)'s 5-year high stood at $0.06 during Q3 2025, with a 5-year trough of -$0.30 in Q1 2022.
  • In the last 3 years, Amicus Therapeutics' EPS (Basic) had a median value of -$0.07 in 2025 and averaged -$0.07.
  • Data for Amicus Therapeutics' EPS (Basic) shows a peak YoY increase of 400.00% (in 2025) and a maximum YoY decrease of 60.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' EPS (Basic) stood at -$0.30 in 2021, then spiked by 33.47% to -$0.20 in 2022, then surged by 44.68% to -$0.11 in 2023, then surged by 145.45% to $0.05 in 2024, then skyrocketed by 400.00% to $0.06 in 2025.
  • Its EPS (Basic) stands at $0.06 for Q3 2025, versus -$0.08 for Q2 2025 and -$0.07 for Q1 2025.